UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda RM, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Marc Tischkowitz M, On behalf of Consensus meeting attendees, Lalloo F.
J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
Mastectomy with one-stage or two-stage reconstruction in breast cancer: analysis of early outcomes and patient's satisfaction.
Angela G, Alessandro P, Alessia T, Michele M, Rossella E, Marco M, Michele T, Giuseppe Massimiliano L, Walter L, Elisabetta P, Paolo PF, Ilaria SL, Giuseppe G, Mario T.
Updates Surg. 2022 Nov 19. doi: 10.1007/s13304-022-01416-0. Epub ahead of print.
Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.
Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA.
JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5228. Epub ahead of print.
Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L, Beekman MJ, Engelhardt EG, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Aaronson NK, Mourits MJE, Van Leeuwen FE.
Am J Obstet Gynecol. 2021 Nov 17. pii: S0002-9378(22)02177-9. doi: 10.1016/j.ajog.2022.11.1289. Epub ahead of print.
Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru.
Zavaleta E, Solis N, Palacios MI, Zevallos-Escobar LE, Vasquez Corales E, Bazo-Alvarez JC, Dominguez-Barrera C, Campos A, Wernhoff P, Ekstrøm PO, Møller P, Visnovska T, Hovig E, Balazar-Palacios J, Alvarez-Valenzuela K, Nakken S, Dominguez-Valentin M.
Cancers (Basel). 2022 Nov 15;14(22):5603. doi: 10.3390/cancers14225603.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES.
Prostate. 2022 Nov 16. doi: 10.1002/pros.24454. Epub ahead of print.
Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment.
Rusnak A, Morrison S, Smith E, Hastings V, Anderson K, Aldridge C, Zelenietz S, Reddick K, Regnier S, Alie E, Islam N, Fasih R, Peddle S, Cordeiro E, Tomiak E, Seely JM.
Curr Oncol. 2022 Nov 15;29(11):8742-8750. doi: 10.3390/curroncol29110688.
Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment.
Rusnak A, Morrison S, Smith E, Hastings V, Anderson K, Aldridge C, Zelenietz S, Reddick K, Regnier S, Alie E, Islam N, Fasih R, Peddle S, Cordeiro E, Tomiak E, Seely JM.
Curr Oncol. 2022 Nov 15;29(11):8742-8750. doi: 10.3390/curroncol29110688.
Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
Abdallah N, Purrington KS, Tatineni S, Assad H, Petrucelli N, Simon MS.
Cancer Causes Control. 2022 Nov 12. doi: 10.1007/s10552-022-01648-w. Epub ahead of print.
Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
Hughes BN, Jorgensen KA, Cummings S, Morah D, Krause K, Rauh-Hain JA, Herzog TJ.
Int J Gynecol Cancer. 2022 Nov 11:ijgc-2022-003913. doi: 10.1136/ijgc-2022-003913. Epub ahead of print.
Malignant Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus as Part of the Hereditary Cancer Syndrome: A Case Diagnosed with Multiple Malignancies.
Caliskan S, Akar OS, Gun S, Kefeli M.
Turk Patoloji Derg. 2022 Dec 11. English. doi: 10.5146/tjpath.2022.01592. Epub ahead of print.
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N.
Cancer Med. 2022 Nov 10. doi: 10.1002/cam4.5333. Epub ahead of print.
Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
De Jong D, Otify M, Chen I, Jackson D, Jayasinghe K, Nugent D, Thangavelu A, Theophilou G, Laios A.
Medicina (Kaunas). 2022 Nov 8;58(11):1611. doi: 10.3390/medicina58111611.